Research programme: diabetic macrovascular disease therapeutics - GlycadiaAlternative Names: CAP 22; GLY-220
Latest Information Update: 02 Aug 2016
At a glance
- Originator Glycadia
- Mechanism of Action Apolipoprotein B inhibitors; Cholesterol inhibitors; Glycosylation inhibitors; Lipid peroxidation inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Diabetic complications
Most Recent Events
- 02 Aug 2016 Investigation in Diabetic complications in USA (unspecified route)